Sensei Bio



Sensei Biotherapeutics is developing an innovative pipeline of first-in-class immune activating agents for a broad array of cancers including solid tumors and hematological malignancies. Our therapies benefit from a precision medicine approach that has the potential to identify patients that will benefit most from our therapies.

Alice Drumheller
VP, Clinical Operations
Edward Van Der Horst
VP, Preclinical Development
Ildiko Csiki
Chief Medical Officer
Jean Campbell
VP, Biologics Discovery
Pauline Callinan
VP, Business Development
Robert Pierce
Chief Scientific Officer
Steven A. Fuller
Chief Biopharmaceuticals Development Officer

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.